Hepion Pharmaceuticals, Inc.
For the period ended Mar 31, 2025. Filed May 19, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 19, 2025
HEPA$0.11-13.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Changes in Stockholders’ Equity
(Unaudited)
| Preferred Stock · Preferred Stock · Additional · Accumulated other · Total | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Series A · Series C · Common Stock · Paid in · Comprehensive · Accumulated · Stockholders’ | ||||||||||
| Shares | Amount | Shares | Amount | Shares | Amount | Capital | Income (Loss) | Deficit | Equity | |
| Balance at December 31, 2023 | 85,581 | $855,808 | 1,688 | $839,320 | 96,375 | $10 | $230,291,834 | $(78,779) | $(224,627,386) | $7,280,807 |
| Net loss | — | — | — | — | — | — | — | — | (2,853,806) | (2,853,806) |
| Other comprehensive income (loss) | — | — | — | — | — | — | — | 87,979 | — | 87,979 |
| Stock-based compensation expense | — | — | — | — | — | — | 705,770 | — | — | 705,770 |
| Warrant exercises, net | — | — | — | — | 13,088 | 1 | 2,300,688 | — | — | 2,300,689 |
| Balance at March 31, 2024 | 85,581 | 855,808 | 1,688 | 839,320 | 109,463 | 11 | 233,298,292 | 9,200 | (227,481,192) | 7,521,439 |
Condensed Consolidated Statements of Changes in Stockholders’ Equity
| Preferred Stock · Preferred Stock · Additional · Accumulated other · Total | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Series A · Series C · Common Stock · Paid in · Comprehensive · Accumulated · Stockholders’ | ||||||||||
| Shares | Amount | Shares | Amount | Shares | Amount | Capital | Income (Loss) | Deficit | Equity | |
| Balance at December 31, 2024 | 85,581 | $855,808 | 1,688 | $839,320 | 139,168 | $14 | $234,252,981 | $8,345 | $(237,819,806) | $(1,863,338) |
| Net loss | — | — | — | — | — | — | — | — | (6,105,887) | (6,105,887) |
| Stock-based compensation expense | — | — | — | — | — | — | 20,783 | — | — | 20,783 |
| Issuance of restricted stock units | — | — | — | — | 1,000 | — | — | — | — | — |
| Issuance of common stock and pre-funded warrants, net | — | — | — | — | 553,846 | 55 | 2,086,537 | — | — | 2,086,592 |
| Issuance of common stock in connection with stock split | — | — | — | — | 60,860 | 6 | (6) | — | — | — |
| Conversion of 2025 Series B warrants into common stock | — | — | — | — | 8,834,034 | 884 | 9,757,029 | — | — | 9,757,913 |
| Balance at March 31, 2025 | 85,581 | 855,808 | 1,688 | 839,320 | 9,588,908 | 959 | 246,117,324 | 8,345 | (243,925,693) | 3,896,063 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.